It’s Déjà Vu All Over Again: FDA Sued Again in Off-Label Promotion Case

by Arnall Golden Gregory LLP
Contact

To quote Yogi Berra, it must feel like déjà vu all over again for the Food and Drug Administration (FDA) (or, if you prefer, Crosby, Stills, Nash & Young’s song, “Déjà Vu” (“We have all been here before”)). Fresh off its recent loss in the Amarin court decision concerning off-label promotion, the agency again finds itself the defendant in another similar lawsuit concerning whether FDA can silence a company’s truthful and non-misleading communications about off-label uses. Our Bulletin on the Amarin decision can be accessed below. This time, it is Pacira Pharmaceuticals, Inc. challenging FDA’s authority. Perhaps not surprisingly, Pacira brought its challenge in the United States District Court for the Southern District of New York, the same forum where FDA lost the Amarin case, hoping for a similar result. 

Background 

Without describing the entire 70+ page Complaint, here are some background facts.

  • Pacira has approval to market its prescription drug, Exparel® (bupivacaine liposome injectable suspension), for single-dose administration into the surgical site to produce post-surgical analgesia.
  • In September 2014, FDA issued a Warning Letter to Pacira, contending that the company promoted its product for pain relief in surgeries not listed in the label, i.e., unapproved and off-label uses, and, thus, misbranded the product.
  • Pacira cites its First Amendment free speech rights to promote its product in a truthful and non-misleading manner (Amarin made similar arguments). The company maintains the information presented is, indeed, consistent with the approved, on-label indication.
  • The company also claims that, under the Due Process Clause of the Fifth Amendment, FDA must establish rules that expressly notify the prohibitions for a particular drug. Pacira asserts that it has a broad, approved indication and, after three years post approval, FDA attempted to limit promotion of the product beyond two specific indications – surgeries for bunions and hemorrhoids. Pacira contends the agency’s regulations as applied to the company are vague. In addition, it alleges FDA failed to provide fair notice about what Pacira could lawfully promote and what FDA considered to be prohibited, thus representing a retroactive, ex post facto penalty.
  • Pacira alleges that FDA violated the Administrative Procedure Act when it attempted to narrow what the company believes was a broad indication, and where it had supporting clinical data for the claims promoted, without following regulatory rules to modify the drug’s label.
  • In the Complaint, Pacira claims it sought to meet with FDA to better understand FDA’s interpretation, but to no avail. FDA ultimately issued a close-out letter to Pacira, indicating it considered the Warning Letter issue to be resolved.
  • Pacira’s Complaint seeks declaratory relief and a preliminary and/or permanent injunction to prevent FDA from taking enforcement action that could violate the company’s legal rights.

AGG Observations 

  • FDA has not responded formally to the lawsuit at this time, so it is not clear how it will argue its case, or if it will take a different position from that asserted in the Amarin case.
  • As noted, the case has been brought in the same jurisdiction where the Aarinm case favored the drug company. Pacira clearly hopes it has a receptive court, but the facts of each case are distinct.
  • FDA has not said much, if anything, post-Amarin, except it is public that Amarin and FDA are discussing settlement options. We believe the agency is struggling to find a balance whereby it can maintain its jurisdictional authority to take enforcement action against what it perceives to be unlawful promotion, while possibility conceding some authority when the off-label information is truthful and not misleading.
  • As we noted in our last Bulletin, one important issue that remains unresolved is who decides what is truthful and not misleading – the company, FDA, or the court. Without this answer, we will likely continue to see companies challenge FDA, particularly in the Southern District of New York.
  • We know, because clients call us daily, that companies, whether pharmaceutical (or biological or medical device), are re-evaluating potential off-label promotional dissemination approaches, in light of recent developments. We remind clients that the courts have not given carte blanche power to manufacturers to promote off-label; we are not (yet) in the Wild West. The information must still be truthful and not misleading, which might require prominent disclosures, disqualifiers or limitations in promotional pieces, among other things. It bears repeating that the Federal Food, Drug, and Cosmetic Act provides that, in determining whether a promotion is misleading, it must be taken into account (among other things) not only representations made or suggested, but also:

the extent to which the labeling or advertising fails to reveal facts material in the light of such representations or material with respect to consequences which may result from the use of the article to which the labeling or advertising relates under the conditions of use prescribed in the labeling, or advertising thereof or under such conditions of use as are customary or usual.

  • A company’s Promotional Review Committee (or PRB, LMR, MLR, or whatever it might be called within a specific company), where we serve as legal representative for many clients, must remain the gatekeeper. Furthermore, non-FDA-related issues, such as False Claims Act prosecution or product liability exposure, must be considered and not discounted or dismissed.

* * * * * 

The Chinese proverb, “May you Live in Interesting Times,” comes to mind. We will continue to follow and provide updates on new developments. 

Downloads:

 It’s Déjà Vu All Over Again: FDA Sued Again in Off-Label Promotion Case

DISCLAIMER: Because of the generality of this update, the information provided herein may not be applicable in all situations and should not be acted upon without specific legal advice based on particular situations.

© Arnall Golden Gregory LLP | Attorney Advertising

Written by:

Arnall Golden Gregory LLP
Contact
more
less

Arnall Golden Gregory LLP on:

Readers' Choice 2017
Reporters on Deadline

"My best business intelligence, in one easy email…"

Your first step to building a free, personalized, morning email brief covering pertinent authors and topics on JD Supra:
Sign up using*

Already signed up? Log in here

*By using the service, you signify your acceptance of JD Supra's Privacy Policy.
Custom Email Digest
Privacy Policy (Updated: October 8, 2015):
hide

JD Supra provides users with access to its legal industry publishing services (the "Service") through its website (the "Website") as well as through other sources. Our policies with regard to data collection and use of personal information of users of the Service, regardless of the manner in which users access the Service, and visitors to the Website are set forth in this statement ("Policy"). By using the Service, you signify your acceptance of this Policy.

Information Collection and Use by JD Supra

JD Supra collects users' names, companies, titles, e-mail address and industry. JD Supra also tracks the pages that users visit, logs IP addresses and aggregates non-personally identifiable user data and browser type. This data is gathered using cookies and other technologies.

The information and data collected is used to authenticate users and to send notifications relating to the Service, including email alerts to which users have subscribed; to manage the Service and Website, to improve the Service and to customize the user's experience. This information is also provided to the authors of the content to give them insight into their readership and help them to improve their content, so that it is most useful for our users.

JD Supra does not sell, rent or otherwise provide your details to third parties, other than to the authors of the content on JD Supra.

If you prefer not to enable cookies, you may change your browser settings to disable cookies; however, please note that rejecting cookies while visiting the Website may result in certain parts of the Website not operating correctly or as efficiently as if cookies were allowed.

Email Choice/Opt-out

Users who opt in to receive emails may choose to no longer receive e-mail updates and newsletters by selecting the "opt-out of future email" option in the email they receive from JD Supra or in their JD Supra account management screen.

Security

JD Supra takes reasonable precautions to insure that user information is kept private. We restrict access to user information to those individuals who reasonably need access to perform their job functions, such as our third party email service, customer service personnel and technical staff. However, please note that no method of transmitting or storing data is completely secure and we cannot guarantee the security of user information. Unauthorized entry or use, hardware or software failure, and other factors may compromise the security of user information at any time.

If you have reason to believe that your interaction with us is no longer secure, you must immediately notify us of the problem by contacting us at info@jdsupra.com. In the unlikely event that we believe that the security of your user information in our possession or control may have been compromised, we may seek to notify you of that development and, if so, will endeavor to do so as promptly as practicable under the circumstances.

Sharing and Disclosure of Information JD Supra Collects

Except as otherwise described in this privacy statement, JD Supra will not disclose personal information to any third party unless we believe that disclosure is necessary to: (1) comply with applicable laws; (2) respond to governmental inquiries or requests; (3) comply with valid legal process; (4) protect the rights, privacy, safety or property of JD Supra, users of the Service, Website visitors or the public; (5) permit us to pursue available remedies or limit the damages that we may sustain; and (6) enforce our Terms & Conditions of Use.

In the event there is a change in the corporate structure of JD Supra such as, but not limited to, merger, consolidation, sale, liquidation or transfer of substantial assets, JD Supra may, in its sole discretion, transfer, sell or assign information collected on and through the Service to one or more affiliated or unaffiliated third parties.

Links to Other Websites

This Website and the Service may contain links to other websites. The operator of such other websites may collect information about you, including through cookies or other technologies. If you are using the Service through the Website and link to another site, you will leave the Website and this Policy will not apply to your use of and activity on those other sites. We encourage you to read the legal notices posted on those sites, including their privacy policies. We shall have no responsibility or liability for your visitation to, and the data collection and use practices of, such other sites. This Policy applies solely to the information collected in connection with your use of this Website and does not apply to any practices conducted offline or in connection with any other websites.

Changes in Our Privacy Policy

We reserve the right to change this Policy at any time. Please refer to the date at the top of this page to determine when this Policy was last revised. Any changes to our privacy policy will become effective upon posting of the revised policy on the Website. By continuing to use the Service or Website following such changes, you will be deemed to have agreed to such changes. If you do not agree with the terms of this Policy, as it may be amended from time to time, in whole or part, please do not continue using the Service or the Website.

Contacting JD Supra

If you have any questions about this privacy statement, the practices of this site, your dealings with this Web site, or if you would like to change any of the information you have provided to us, please contact us at: info@jdsupra.com.

- hide
*With LinkedIn, you don't need to create a separate login to manage your free JD Supra account, and we can make suggestions based on your needs and interests. We will not post anything on LinkedIn in your name. Or, sign up using your email address.